Brief: Longeveron Says Study Results From Clear Mind Phase 2A Clinical Trial Of Lomecel-B™ Achieved Primary Safety & Secondary Efficacy Endpoints
28/07/2024 21:52
July 28 (Reuters) - Longeveron Inc LGVN.O :
* LONGEVERON® PRESENTS STUDY RESULTS FROM CLEAR MIND PHASE
2A
CLINICAL TRIAL OF LOMECEL-B™ IN MILD ALZHEIMER’S DISEASE AT THE
ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE® (AAIC)
* LONGEVERON INC: CLINICAL TRIAL ACHIEVED ITS PRIMARY SAFETY
AND
SECONDARY EFFICACY ENDPOINTS
Source text for Eikon: ID:nGNX9dFfrc
Further company coverage: LGVN.O
((Reuters.Briefs@thomsonreuters.com;))